The latest achievements in sensor technologies for blood glucose level monitoring, pump miniaturization for insulin delivery, and the availability of portable computing devices are paving the way toward the artificial pancreas as a treatment for diabetes patients. This device encompasses a controller unit that oversees the administration of insulin micro-boluses and continuously drives the pump based on blood glucose readings acquired in real time. In order to foster the research on the artificial pancreas and prepare for its adoption as a therapy, the European Union in 2010 funded the AP@home project, following a series of efforts already ongoing in the USA. This paper, authored by members of the AP@home consortium, reports on the technical issues concerning the design and implementation of an architecture supporting the exploitation of an artificial pancreas platform. First a PC-based platform was developed by the authors to prove the effectiveness and reliability of the algorithms responsible for insulin administration. A mobile-based one was then adopted to improve the comfort for the patients. Both platforms were tested on real patients, and a description of the goals, the achievements, and the major shortcomings that emerged during those trials is also reported in the paper.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11517-014-1231-1 | DOI Listing |
Sci Rep
January 2025
Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Republic of Korea.
Given the increasing trend of cholecystectomy, it is imperative to reassess surgical and surveillance strategies in consideration of the potential long-term risks for digestive tract cancers. The objective of this study was to assess the risk of gastrointestinal (GI) and hepato-biliary-pancreatic (HBP) cancer incidence after cholecystectomy. The data for this cohort study was obtained from the National Health Insurance Service database in Korea.
View Article and Find Full Text PDFAbdom Radiol (NY)
December 2024
Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths in the United States, largely due to its poor five-year survival rate and frequent late-stage diagnosis. A significant barrier to early detection even in high-risk cohorts is that the pancreas often appears morphologically normal during the pre-diagnostic phase. Yet, the disease can progress rapidly from subclinical stages to widespread metastasis, undermining the effectiveness of screening.
View Article and Find Full Text PDFSemin Cancer Biol
December 2024
Department of Biology, University of Pisa, Pisa, Italy. Electronic address:
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal and common form of pancreatic cancer, it has no specific symptoms, and most of the patients are diagnosed when the disease is already at an advanced stage. Chemotherapy typically has only a modest effect, making surgery the most effective treatment option. However, only a small percentage of patients are amenable to surgery.
View Article and Find Full Text PDFStem Cell Res Ther
December 2024
Department of Central Laboratory, Shenzhen Hospital, Beijing University of Chinese Medicine, Shenzhen, Guangdong, China.
Background: The simultaneous differentiation of human pluripotent stem cells (hPSCs) into both endodermal and mesodermal lineages is crucial for developing complex, vascularized tissues, yet poses significant challenges. This study explores a method for co-differentiation of mesoderm and endoderm, and their subsequent differentiation into pancreatic progenitors (PP) with endothelial cells (EC).
Methods: Two hPSC lines were utilized.
Diabetes Metab
December 2024
Institut de recherches cliniques de Montréal, Canada; Département de Nutrition, Faculté de Médecine, Université de Montréal, Canada; Endocrinology Division and Montreal Diabetes Research Center, Canada. Electronic address:
Objective: We investigated strategies to mitigate hypoglycemic risk during and after different aerobic exercises in people with type 1 diabetes (pwT1D) using continuous subcutaneous insulin infusion.
Research Design And Methods: Thirty-seven pwT1D (21 adults, 16 adolescents; HbA1c = 7.5 ± 1.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!